Answers are grounded in this paper and cite their sources.
Since the discovery of the first embryonic stem cells (ESCs) from mice (Evans & Kaufman, 1981; Martin, 1981), in vitro study on the mechanisms of neural development and neural degenerative disorders never stops (Berberi et al., 2003; Kawasaki et al., 2000;Lee et al., 2000; Lu & Song, 2006; Lu et al., 2009;Pacherik et al., 2002; Strübing et al., 1995; Tropepe et al., 2001; Ying et al., 2003).With the isolation of the first human ESCs (Thomson et al., 1998), the dream of using these magic cells to understand the human being’s brain and to treat the neural degenerative diseases starts showing in scientists’ and clinicians’ thoughts. In 2006 and 2007, Yamanaka group and Thomson group successfully generated mouse and human induced pluripotent stem cells (iPSCs) (Takahashi&Yamanaka, 2006; Takahashi, et al., 2007; Yu et al., 2007), which not only overcomes the ethical issues brought by the isolation human ESCs,but also may in theory avoid immunosuppression reactions after autologous transplantation. This creation makes it possible to study the individualized human cells in vitro, especially the neural cells in the central nervous system (CNS), which usually are hard to obtain from live human beings. Human pluripotent stem cells (PSCs) derived neural cells have been globally used in the two major areas in neurosciences: 1. Research on human neural system development and neural degenerative diseases’ pathophysiologic process, which may help researchers find potential targets to treat diseases; 2. PSCs based pre-clinical/ clinical cell therapies(a part of personalized medical treatments).
No takes yet. Share an insight, caveat, or question.
Jian Lü (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: